Glenmark Pharmaceuticals Inc. USA Launches Generic Olanzapine for Injection, Targets $25.4 Million Market

Glenmark Pharmaceuticals Inc., USA – a vital part of the global pharmaceutical leader Glenmark Pharmaceuticals Limited – has strategically expanded its reach in the U.S. healthcare sector. The company is pleased to announce today the launch of Olanzapine for Injection, 10 mg/vial (Single-Dose Vial), set to begin on July 6, 2026.

Glenmark Pharmaceuticals Inc., USA – a vital part of the global pharmaceutical leader Glenmark Pharmaceuticals Limited – has strategically expanded its reach in the U.S. healthcare sector. The company is pleased to announce today the launch of Olanzapine for Injection (10 mg/vial; Single-Dose Vial formulation), effective July 6, 2026.

This introduction solidifies Glenmark’s position within the crucial U.S. institutional healthcare market by adding a valuable addition to its already robust injectables portfolio.

The newly launched product is bioequivalent and therapeutically equivalent to Cheplapharm Registration GmbH’s Zyprexa® IntraMuscular Injection (10 mg/vial), guaranteeing healthcare providers that it offers comparable efficacy and safety. Entering the generic market for this widely prescribed medication signifies a direct challenge, demonstrating Glenmark’s dedication to providing high-quality, accessible pharmaceutical alternatives.

Financially, this launch presents considerable opportunity. IQVIA® data from May 2026 indicates substantial annual sales for Zyprexa Intramuscular Injection in that timeframe:

Annual Market Sales (up to May 2026): Approximately $25.4 million

Commenting on the strategic importance, Marc Kikuchi, President & Business Head, North America, said: “The launch of Olanzapine injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel.”

This initiative perfectly aligns with Glenmark’s overarching goal to enhance access to affordable treatments across various therapeutic areas. Leveraging its status as a global, research-driven company operating in 80+ countries and recognized as one of the top biopharmaceutical firms worldwide, Glenmark is expected to make a significant contribution to its market share and financial growth with this new generic offering.